Table 1.
Characteristics for the original matched study patients (N = 130) and the patients with SPP1 gene expression data measured by qPCR (N = 100) and OPN protein expression (N = 116). SD = standard deviation, PR = Progresterone receptor, HER2 = Human epidermal growth factor receptor 2, Rad = Radiation therapy Cyt = Cytostatic drugs, n.a. = non available.
| Total | Orignial cohort (N = 130) | p-valuea | SPP1 gene expression (N = 100) | p-valuea | OPN protein expression (N = 116) | p-valuea | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Recurrence | Non-recurrence | Recurrence | Non-recurrence | Recurrence | Non-recurrence | |||||
| N (column %) | N (column %) | N (column %) | N (column %) | N (column %) | N (column %) | |||||
| 27 (100) | 103 (100) | 25 (100) | 75 (100) | 27 (100) | 89 (100) | |||||
| Mean age at diagnosis (years ± SD) | 56.6 ( ± 12.8) | 63.5 ( ± 14.6) | 0.027c | 56.9 ( ± 13.2) | 63.7 ( ± 14.3) | 0.038c | 56.6 ( ± 12.8) | 65.3 ( ± 14.2) | 0.005c | |
| Mean tumour size (mm ± SD) | 36.4 ( ± 29.6) | 28.3 ( ± 18.0) | 0.18d | 34.1 ( ± 29.6) | 26.7 ( ± 16.4) | 0.24d | 36.4 ( ± 29.6) | 27.5 ( ± 17.0) | 0.15d | |
| Tumour size by 20th percentile* | 1 (10–15 mm) | 5 (18.5) | 20 (19.4) | 0.65 | 5 (20.0) | 15 (20.0) | 0.69 | 5 (18.5) | 17 (19.1) | 0.39 |
| 2 (16–20 mm) | 5 (18.5) | 24 (23.3) | 5 (20.0) | 19 (25.3) | 5 (18.5) | 21 (23.6) | ||||
| 3 (21–28 mm) | 5 (18.5) | 20 (19.4) | 5 (20.0) | 14 (18.7) | 5 (18.5) | 19 (21.3) | ||||
| 4 (30–35 mm) | 3 (11.1) | 19 (18.4) | 3 (12.0) | 15 (20.0) | 3 (11.1) | 18 (20.2) | ||||
| 5 (40–150 mm) | 9 (33.3) | 20 (19.4) | 7 (28.0) | 12 (16.0) | 9 (33.3) | 14 (15.7) | ||||
| Grade (Elston) | I | 2 (7.4) | 15 (14.6) | 0.64 | 2 (8.0) | 11 (14.7) | 0.72 | 2 (7.4) | 11 (12.4) | 0.73 |
| II | 16 (59.3) | 60 (58.3) | 14 (56.0) | 41 (54.7) | 16 (59.3) | 54 (60.7) | ||||
| III | 9 (33.3) | 28 (27.2) | 9 (36.0) | 23 (30.7) | 9 (33.3) | 24 (27.0) | ||||
| Menopausal status* | Pre- | 11 (40.7) | 25 (24.3) | 0.097b | 10 (40.0) | 17 (22.7) | 0.12b | 11 (40.7) | 17 (19.1) | 0.038b |
| Post- | 16 (59.3) | 78 (75.7) | 15 (60.0) | 58 (77.3) | 16 (59.3) | 72 (80.9) | ||||
| PR-Status | Negative | 3 (11.1) | 13 (12.6) | 1.00/0.29e | 3 (12.0) | 11 (14.7) | 1.00/0.39e | 3 (11.1) | 12 (13.5) | 1.00/0.38e |
| Positive | 23 (85.2) | 90 (87.4) | 21 (84.0) | 64 (85.3) | 23 (85.2) | 77 (86.5) | ||||
| n.a. | 1 (3.7) | 0 (0.0) | 1 (4.0) | 0 (0.0) | 1 (3.7) | 0 (0.0) | ||||
| Lymph node infiltration* | No | 8 (29.6) | 35 (34.0) | 0.82b | 8 (32.0) | 28 (37.3) | 0.81b | 8 (29.6) | 32 (36.0) | 0.65b |
| ≥ 1 | 19 (70.4) | 68 (66.0) | 17 (68.0) | 47 (62.7) | 19 (70.4) | 57 (64.0) | ||||
| HER2 | Negative | 21 (77.8) | 66 (64.1) | 1.00/0.24e | 21 (84.0) | 57 (76.0) | 1.00/0.60e | 21 (77.8) | 59 (66.3) | 1.00/0.37e |
| Positive | 3 (11.1) | 10 (9.7) | 3 (12.0) | 9 (12.0) | 3 (11.1) | 9 (10.1) | ||||
| n.a. | 3 (11.1) | 27 (26.2) | 1 (4.0) | 9 (12.0) | 3 (11.1) | 21 (23.6) | ||||
| Aromatase inhibitors | No | 26 (96.3) | 90 (87.4) | 0.30 | 24 (96.0) | 64 (85.3) | 0.29 | 26 (96.3) | 77 (86.5) | 0.29 |
| Yes | 1 (3.7) | 13 (12.6) | 1 (4.0) | 11 (14.7) | 1 (3.7) | 12 (13.5) | ||||
| Trastuzumab treatment | No | 25 (92.6) | 102 (99.0) | 0.11 | 23 (92.0) | 74 (98.7) | 0.15 | 25 (92.6) | 88 (98.9) | 0.14 |
| Yes | 2 (7.4) | 1 (1.0) | 2 (8.0) | 1 (1.3) | 2 (7.4) | 1 (1.1) | ||||
| Additional treatment | No other | 1 (3.7) | 16 (15.5) | 0.075 | 1 (4.0) | 12 (16.0) | 0.11 | 1 (3.7) | 16 (18.0) | 0.032 |
| Rad | 9 (33.3) | 46 (44.7) | 9 (36.0) | 34 (45.3) | 9 (33.3) | 41 (46.1) | ||||
| Rad and cyt | 17 (63.0) | 41 (39.8) | 15 (60.0) | 29 (38.7) | 17 (63.0) | 32 (36.0) | ||||
*Matching criteria, aFisher’s Exact Test if not else is specified (cells with expected counts < 5). bChi2-test (all cells with expected count > 5). cStudent’s T-test, equal variances assumed, dStudent’s T-test, equal variances not assumed (Lavene’s test p < 0.05). eChi2-test including cases with n.a.